CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

ANCA-associated Vasculitis

Conditions

ANCA-associated Vasculitis

Trial Timeline

Feb 4, 2015 → Jul 19, 2016

NCT ID

NCT02222155

About CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids

CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids is a phase 2 stage product being developed by Amgen for ANCA-associated Vasculitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02222155. Target conditions include ANCA-associated Vasculitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02222155	Phase 2	Completed	Feb 4, 2015	Jul 19, 2016	ANCA-associated Vasculitis

Competing Products

3 competing products in ANCA-associated Vasculitis

See all competitors

Product	Company	Stage	Hype Score
rituximab + Placebo	Roche	Phase 3	77
Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine	Amgen	Phase 3	76
Abatacept (Orencia)	Bristol Myers Squibb	Phase 2	51

Other Products from Amgen